KaloBios to Present at Future Leaders in the Biotech Industry Conference
SOUTH SAN FRANCISCO, Calif., April 1, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company has been selected to present at the 2013 BioCentury-Thomson Reuters Future Leaders in the Biotech Industry Conference, to be held in New York City on April 5, 2013. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.
When: Friday, April 5, 2013, 9:00 am EDT, Presentation Room 311
Where: Millennium Broadway Hotel and Conference Center, New York, NY
To access the live and archived audio webcast of the KaloBios Future Leaders presentation please log on through a link located in the Investors section of the KaloBios Pharmaceuticals website under the Events & Presentations tab: http://ir.kalobios.com/events.cfm.
A replay of the webcast will be available one hour after the conclusion of the live event.
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.
Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
Joan E. Kureczka
Tel: (415) 821-2413
Mobile: (415) 690-0210
SOURCE KaloBios Pharmaceuticals, Inc.
More by this Source
KaloBios Initiates Phase 2 Expansion Portion of Study of KB004 in Hematologic Malignancies
Feb 11, 2014, 08:00 ET
KaloBios Announces Upcoming Webcasts and Conference Participation
Feb 05, 2014, 18:00 ET
KaloBios Reports Top-Line Data for Phase 2 Study of KB003 in Severe Asthma
Jan 29, 2014, 16:01 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.